THE IMPACT OF 68GA-PSMA PET/CT ON THERAPY MANAGEMENT OF HIGH RISK PROSTATE CANCER
Objective: We evaluated the impact of 68Ga-PSMA PET/CT (PSMA PET) on therapy management of newly diagnosed highrisk prostate cancer (PCa). Material and Method: Patients who underwent a PSMA PET for primary staging of high-risk PCa were evaluated retrospectively. Patients had abdominopelvic CT (n=126...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Istanbul University Press
2021-01-01
|
| Series: | İstanbul Tıp Fakültesi Dergisi |
| Subjects: | |
| Online Access: | https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/D47CFD0796FA4E0BA1017BED1424C4E4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850034727376912384 |
|---|---|
| author | Duygu Has Şimşek Emine Göknur Işık Caner Civan Zeynep Gözde Özkan Serkan Kuyumcu Ayça İribaş Mehmet Öner Şanlı Yasemin Şanlı |
| author_facet | Duygu Has Şimşek Emine Göknur Işık Caner Civan Zeynep Gözde Özkan Serkan Kuyumcu Ayça İribaş Mehmet Öner Şanlı Yasemin Şanlı |
| author_sort | Duygu Has Şimşek |
| collection | DOAJ |
| description | Objective: We evaluated the impact of 68Ga-PSMA PET/CT (PSMA PET) on therapy management of newly diagnosed highrisk prostate cancer (PCa). Material and Method: Patients who underwent a PSMA PET for primary staging of high-risk PCa were evaluated retrospectively. Patients had abdominopelvic CT (n=126), pelvic MRI (n=42) and bone scintigraphy (BS) (n=40) prior to PSMA PET. All clinical, biochemical, and imaging data were documented. Increased PSMA uptakes related to PCa were documented according to previously described PSMA-RADS version 1.0 based on a fivepoint scale. The impact of PSMA PET on patient management was evaluated through pre and post PET/CT questionnaires, retrospectively. Management changes were categorized as inter or intramodality change, based on PSMA PET results. Paired samples t-test was used to compare subgroups in SPSS version 24.0 software. A p-value <0.05 was considered significant. Results: A total of 126 patients were included in the study. The median PSA level was 30.8 ng/ml (95%CI: 2.1-268.6 ng/ml) and median GS was 8 (range: 6-10). Based on the PSMA PET findings, 41 patients (32.5%) had more extensive disease and 2 patients (1.6%) had less extensive disease. Overall, therapy management was changed in 38 patients (30.1%). Intermodality changes occurred in 29 patients (23%), and intramodality changes occurred in 9 patients (7.1%). The change in management was similar in patients with BS and without BS, 30% vs. 30.2%. Conclusion: PSMA PET impacted the therapy management in almost one-third of patients in high-risk PCa even though they had already been staged with standard imaging modalities. |
| format | Article |
| id | doaj-art-e96be72d5c2747ffabd9ae95383ecc6e |
| institution | DOAJ |
| issn | 1305-6441 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Istanbul University Press |
| record_format | Article |
| series | İstanbul Tıp Fakültesi Dergisi |
| spelling | doaj-art-e96be72d5c2747ffabd9ae95383ecc6e2025-08-20T02:57:43ZengIstanbul University Pressİstanbul Tıp Fakültesi Dergisi1305-64412021-01-01841485610.26650/IUITFD.2020.831103123456THE IMPACT OF 68GA-PSMA PET/CT ON THERAPY MANAGEMENT OF HIGH RISK PROSTATE CANCERDuygu Has Şimşek0https://orcid.org/0000-0001-6945-2003Emine Göknur Işık1https://orcid.org/0000-0002-3786-8052Caner Civan2https://orcid.org/0000-0003-4745-3501Zeynep Gözde Özkan3https://orcid.org/0000-0003-0360-358XSerkan Kuyumcu4https://orcid.org/0000-0002-1158-5361Ayça İribaş5https://orcid.org/0000-0002-1686-7114Mehmet Öner Şanlı6https://orcid.org/0000-0001-5801-6898Yasemin Şanlı7https://orcid.org/0000-0002-1267-2379İstanbul Üniversitesi, İstanbul, Türkiyeİstanbul Üniversitesi, İstanbul, Türkiyeİstanbul Üniversitesi, İstanbul, Türkiyeİstanbul Üniversitesi, İstanbul, Türkiyeİstanbul Üniversitesi, İstanbul, Türkiyeİstanbul Üniversitesi, İstanbul, Türkiyeİstanbul Üniversitesi, İstanbul, Türkiyeİstanbul Üniversitesi, İstanbul, TürkiyeObjective: We evaluated the impact of 68Ga-PSMA PET/CT (PSMA PET) on therapy management of newly diagnosed highrisk prostate cancer (PCa). Material and Method: Patients who underwent a PSMA PET for primary staging of high-risk PCa were evaluated retrospectively. Patients had abdominopelvic CT (n=126), pelvic MRI (n=42) and bone scintigraphy (BS) (n=40) prior to PSMA PET. All clinical, biochemical, and imaging data were documented. Increased PSMA uptakes related to PCa were documented according to previously described PSMA-RADS version 1.0 based on a fivepoint scale. The impact of PSMA PET on patient management was evaluated through pre and post PET/CT questionnaires, retrospectively. Management changes were categorized as inter or intramodality change, based on PSMA PET results. Paired samples t-test was used to compare subgroups in SPSS version 24.0 software. A p-value <0.05 was considered significant. Results: A total of 126 patients were included in the study. The median PSA level was 30.8 ng/ml (95%CI: 2.1-268.6 ng/ml) and median GS was 8 (range: 6-10). Based on the PSMA PET findings, 41 patients (32.5%) had more extensive disease and 2 patients (1.6%) had less extensive disease. Overall, therapy management was changed in 38 patients (30.1%). Intermodality changes occurred in 29 patients (23%), and intramodality changes occurred in 9 patients (7.1%). The change in management was similar in patients with BS and without BS, 30% vs. 30.2%. Conclusion: PSMA PET impacted the therapy management in almost one-third of patients in high-risk PCa even though they had already been staged with standard imaging modalities.https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/D47CFD0796FA4E0BA1017BED1424C4E468ga-psma pet/ctprostate cancerstagingtherapy management |
| spellingShingle | Duygu Has Şimşek Emine Göknur Işık Caner Civan Zeynep Gözde Özkan Serkan Kuyumcu Ayça İribaş Mehmet Öner Şanlı Yasemin Şanlı THE IMPACT OF 68GA-PSMA PET/CT ON THERAPY MANAGEMENT OF HIGH RISK PROSTATE CANCER İstanbul Tıp Fakültesi Dergisi 68ga-psma pet/ct prostate cancer staging therapy management |
| title | THE IMPACT OF 68GA-PSMA PET/CT ON THERAPY MANAGEMENT OF HIGH RISK PROSTATE CANCER |
| title_full | THE IMPACT OF 68GA-PSMA PET/CT ON THERAPY MANAGEMENT OF HIGH RISK PROSTATE CANCER |
| title_fullStr | THE IMPACT OF 68GA-PSMA PET/CT ON THERAPY MANAGEMENT OF HIGH RISK PROSTATE CANCER |
| title_full_unstemmed | THE IMPACT OF 68GA-PSMA PET/CT ON THERAPY MANAGEMENT OF HIGH RISK PROSTATE CANCER |
| title_short | THE IMPACT OF 68GA-PSMA PET/CT ON THERAPY MANAGEMENT OF HIGH RISK PROSTATE CANCER |
| title_sort | impact of 68ga psma pet ct on therapy management of high risk prostate cancer |
| topic | 68ga-psma pet/ct prostate cancer staging therapy management |
| url | https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/D47CFD0796FA4E0BA1017BED1424C4E4 |
| work_keys_str_mv | AT duyguhassimsek theimpactof68gapsmapetctontherapymanagementofhighriskprostatecancer AT eminegoknurisık theimpactof68gapsmapetctontherapymanagementofhighriskprostatecancer AT canercivan theimpactof68gapsmapetctontherapymanagementofhighriskprostatecancer AT zeynepgozdeozkan theimpactof68gapsmapetctontherapymanagementofhighriskprostatecancer AT serkankuyumcu theimpactof68gapsmapetctontherapymanagementofhighriskprostatecancer AT aycairibas theimpactof68gapsmapetctontherapymanagementofhighriskprostatecancer AT mehmetonersanlı theimpactof68gapsmapetctontherapymanagementofhighriskprostatecancer AT yaseminsanlı theimpactof68gapsmapetctontherapymanagementofhighriskprostatecancer AT duyguhassimsek impactof68gapsmapetctontherapymanagementofhighriskprostatecancer AT eminegoknurisık impactof68gapsmapetctontherapymanagementofhighriskprostatecancer AT canercivan impactof68gapsmapetctontherapymanagementofhighriskprostatecancer AT zeynepgozdeozkan impactof68gapsmapetctontherapymanagementofhighriskprostatecancer AT serkankuyumcu impactof68gapsmapetctontherapymanagementofhighriskprostatecancer AT aycairibas impactof68gapsmapetctontherapymanagementofhighriskprostatecancer AT mehmetonersanlı impactof68gapsmapetctontherapymanagementofhighriskprostatecancer AT yaseminsanlı impactof68gapsmapetctontherapymanagementofhighriskprostatecancer |